Rinascera Therapeutics
Boston, US · Founded 2025 · Delaware corporation · 1 known investors
Founders & leadership
NE
Nichola EliovitsExecutive
MD
Max DawsonExecutive
KB
Karl BeutnerExecutive
Board
DY
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2025
▶$2.5MraisedOct 2025 · 3 investors · BiotechnologyRule 506(b)
▶$2.5MraisedOct 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nichola EliovitsExecutive Officer, Director
- Max DawsonExecutive Officer
- Daniel YadegarDirector
- Karl BeutnerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Rinascera Therapeutics's investors?
- Rinascera Therapeutics's investors include Newpath Partners.
- How much funding has Rinascera Therapeutics raised?
- Rinascera Therapeutics has disclosed $2.5M raised across 1 round.
- Where is Rinascera Therapeutics headquartered?
- Rinascera Therapeutics is headquartered in Boston, US.